Writing in Advances in Drug and Alcohol Research, Aina Afini Abd Basir and Zalmizy Hussin of Universiti Utara Malaysia propose that custody and re-entry be investigated as a neuropeptide-sensitive allostatic sequence. Allostasis refers to the body’s active process of maintaining stability through change—recalibrating stress systems as circumstances shift. The authors define what they call the “carceral allostatic amplifier”: an exposure-linked, within-person worsening of stress-regulatory phenotypes across custody and re-entry, potentially accompanied by coordinated changes in candidate neuropeptide measures. Crucially, they present this as a conditional and falsifiable construct, not a biological label. It predicts neither uniform harm across all institutions nor a common trajectory for all incarcerated people; its purpose is to identify when abrupt environmental change, interrupted care, and preexisting dysregulation may converge.

The technical backbone of the framework comes from decades of stress-related addiction neurobiology. Addiction involves adaptations in reward circuitry alongside recruitment of stress processes in the extended amygdala. The primary stress-promoting candidates in this model are corticotropin-releasing factor (CRF), dynorphin acting at kappa opioid receptors, and orexin signaling. Arrayed against them are counter-regulatory candidates: neuropeptide Y, nociceptin, and context-dependent oxytocin. Their roles vary by receptor, circuit, substance, and addiction stage. The authors are careful to note that peripheral concentrations—measured in blood, serum, or saliva—are indirect and cannot be equated with synaptic release, receptor activity, or signaling within a specific brain circuit. Notably, they are unaware of any prospective human studies that repeatedly measure neuropeptide trajectories from custody through community re-entry, which is precisely the gap their agenda targets.

Why does observed non-use under constraint conceal allostatic vulnerability? The answer lies in timing. Risk is concentrated immediately after release, and a program assessed only at discharge may appear successful before community cues and structural adversity have tested what was achieved in custody. Release reintroduces drug-associated cues while adding pressures related to housing, stigma, income, and unstable treatment access. When return to use occurs, it is often attributed to motivation alone, even though vulnerability may have accumulated silently before release. Follow-up, the authors argue, should align with the biological and social transition rather than administrative convenience.

The framework is deliberately transdiagnostic at the level of stress regulation, but the authors warn it should not be assumed to operate identically across substances or populations. Alcohol, opioid, stimulant, and polysubstance use disorders require stratified analyses, as do co-occurring trauma, mental illness, chronic pain, sex-related biology, age, and treatment exposure. Opioid use disorder offers a pragmatic initial test because the correctional-care evidence is strongest for medication continuity and post-release outcomes—randomized trials of prison-initiated buprenorphine and methadone continuation versus forced withdrawal, along with New York City jail data linking jail-based methadone or buprenorphine treatment to lower overdose mortality after release. Findings should not be generalized automatically to other disorders.

The authors reject the seductive prospect of a single blood marker for relapse as premature. Plasma, serum, saliva, and other peripheral specimens are not interchangeable, and their concentrations may not represent central signaling. Circadian timing, nutrition, medication, acute stress, sex-related biology, specimen handling, extraction, storage, and assay procedures can all influence results. Oxytocin illustrates the uncertainty: peripheral measurement is methodologically sensitive, and a recent randomized controlled trial found no added benefit of intranasal oxytocin beyond alcohol behavioral couple therapy. Instead, they propose a within-person network hypothesis: under sustained adversity, greater recruitment of stress-promoting systems together with insufficient counter-regulation may accompany hyperarousal, poor sleep, reduced social safety, stress-reactive craving, and diminished recovery motivation. Housing, stigma, relationships, income, and treatment access are not background noise; depending on the causal question, they may be exposures, moderators, mediators, or outcomes.

The model yields four prespecified, falsifiable predictions. First, within-person changes in stress-regulatory phenotypes will cluster around defined transitions—custody entry, stable custody, release preparation, and re-entry—rather than remain static. Second, greater exposure to sleep disruption, social threat, cue exposure, or treatment interruption will be associated with less favorable trajectories, whereas medication continuity and trusted care will attenuate them. Third, repeated measures will explain more variation in proximal outcomes than a single pre-release value. Fourth, the construct will be weakened if standardized assays show no reproducible transition-related pattern or no incremental information beyond contextual and clinical measures. An informative design would follow participants at custody entry, during stable custody, before release, within 72 hours after release where feasible, during weeks one and two, and at days 30 and 90—with prespecified specimen matrices, standardized collection timing, blinded duplicate assays, and validated measures of sleep, stress, social safety, craving, cue exposure, housing, and treatment continuity.

The authors also draw a sharp line between three potential uses of neuropeptide measures that must remain distinct. A mechanistic correlate may illuminate a pathway without predicting an individual outcome. A prognostic biomarker must add validated predictive value beyond available clinical and social information. A treatment-response biomarker must identify differential benefit from a defined intervention. Candidate neuropeptides are far from satisfying the latter two standards. The immediate question is whether coordinated, context-linked trajectories are reproducible—not whether a threshold can classify an individual. Ethical guardrails are equally explicit: medication for substance use disorder must never be withheld for mechanistic convenience, consent must be voluntary and separated from discipline, privileges, parole, and release decisions, and biospecimens and linked data should never be repurposed for punishment, surveillance, or individualized release prediction. People with lived experience should participate in protocol design, oversight, and interpretation.

On treatment, the practical priority is continuity before precision. Evidence-based medication should continue across custody and release, and sleep stabilization, predictable routines, dependable social connection, naloxone access, housing support, and timely community linkage are justified by clinical and ethical evidence independent of any biomarker. Humane care must never become conditional on a biological result. Neuropeptide-targeted treatment remains experimental: nivasorexant, the first selective orexin-1 receptor antagonist investigated in clinical trials, entered human studies for non-addiction indications, but efficacy for addiction has not been established, and a newer selective orexin-1 antagonist has progressed from preclinical substance-use models toward early human investigation without clinical efficacy evidence to date. The defensible near-term agenda is mechanism-focused research layered onto established medication, housing, harm reduction, and psychosocial care—not a replacement for those interventions.

The carceral allostatic amplifier is deliberately falsifiable. It would be weakened if repeated, standardized measures showed no reproducible transition-related pattern, added no information beyond contextual measures, or failed to track proximal phenotypes after rigorous control for confounding. It would be strengthened by convergence across repeated assays, sleep and behavioral phenotypes, and experimental stress responses. Even convergent peripheral findings would remain correlates unless stronger causal designs supported mediation. The model’s contributions are threefold: it explains why observed non-use under constraint may overstate recovery, it integrates structural exposure with stress biology without treating either as sufficient, and it redirects biomarker research from static classification toward dynamic transitions. Its limitations are substantial—human neuropeptide measurement is difficult, translation from animal models is incomplete, correctional environments are heterogeneous, and observational studies are vulnerable to selection, attrition, measurement error, and time-varying confounding. The authors do not advocate neuropeptide screening of incarcerated people. Their conclusion requires no biomarker validation at all: pharmacological, relational, and environmental continuity should be preserved across the gate, and neuropeptide science will be useful only if it clarifies how to strengthen that continuity rather than reducing addiction to a molecule.

Subject of Research: The prison-to-community transition as a neuropeptide stress test: an allostatic continuity agenda for addiction care

Article Title: The prison-to-community transition as a neuropeptide stress test: an allostatic continuity agenda for addiction care

Article References: Abd Basir, A. A., & Hussin, Z. (2026). The prison-to-community transition as a neuropeptide stress test: an allostatic continuity agenda for addiction care. Advances in Drug and Alcohol Research, 6, Article 17562. https://doi.org/10.3389/adar.2026.17562

Image Credits: AI Generated

DOI: 10.3389/adar.2026.17562

Keywords: prison-to-community, transition, neuropeptide, stress, test, allostatic, continuity, agenda, addiction, care, scientific research